Dublin-based FIRE1 today announced that the first Irish patient has been successfully implanted with its FIRE1 System for remote heart failure monitoring. The innovative system has the potential to positively
Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.
A JAK1 selective inhibitor could soon become a standard treatment option for people with atopic dermatitis, according to a new Irish study. The findings
Trinity College Dublin and St James s Hospital, Dublin clinical trials reported efficacy and safety results of upadacitinib compared with placebo for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents. This pivotal Global Phase 3 study involved 1,600 patients and took place over a two-year period. Results show the drug to so far be the most effective treatment for atopic dermatitis in clinical trials.
Trial results show upadacitinib to be the most effective treatment for atopic dermatitis
The findings of a clinical trial by Trinity College Dublin researchers of treatment for atopic dermatitis have been published today in
The Lancet journal (Friday, 21st May, 2021). Results of the clinical trial at the School of Medicine, Trinity College and St James s Hospital, Dublin have shown the drug upadacitinib to be the most effective treatment to date for this chronic, relapsing inflammatory condition. The research is vital as there is an unmet need which exists for therapies that provide remission of symptoms in moderate-to-severe atopic dermatitis.
The publication reports efficacy and safety results of upadacitinib compared with placebo for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents. This pivotal Global Phase 3 study involved 1,600 patients and took place over the last two years at The Wellcome Trust/Health Research Board Clinical Research Facilit